FDA Approves Brexpiprazole for Agitation Associated with Alzheimer Dementia
The approval makes brexpiprazole, an atypical antipsychotic, the first and only treatment approved in the United States for this common neuropsychiatric symptom of AD, which is reported in nearly half…
